Completed PHASE4 NCT00199004

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)

Sponsor: Johann Wolfgang Goethe University Hospital

Conditions Adult Acute Lymphocytic Leukemia

Interventions Adriamycin Asparaginase CNS irradiation Cyclophosphamide Cytarabine Daunorubicin Dexamethasone / Prednisolone G-CSF Mediastinal irradiation (if residual TU) Mercaptopurine Methotrexate Rituximab Stem cell transplantation Thioguanine VM26 VP16 Vincristine Vindesine

Updated 5 times since 2017 Last updated: Aug 20, 2010 Started: Apr 30, 2004 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

Listed as NCT00199004, this PHASE4 trial focuses on Adult Acute Lymphocytic Leukemia and remains completed. Sponsored by Johann Wolfgang Goethe University Hospital, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johann Wolfgang Goethe University Hospital

Data source: Johann Wolfgang Goethe University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Frankfurt, Germany